Oramed Pharmaceuticals Investor Presentation — January 2022

Document content

Addressing the Multibillion- Dollar

Injectable Drug Markets with Oral

January 20222Safe Harbor

Certain statements contained inthis material areforward -looking statements .These forward -looking statements arebased on

the current expectations ofthe management ofOramed only, including with respect toclinical trials, milestones and the

potential benefits ofOramed's products, and aresubject toanumber offactors and uncertainties that could cause actual results

todiffer materially from those described intheforward -looking statements, including therisks and uncertainties related tothe

progress, timing, cost, and results ofclinical trials and product development programs ;difficulties ordelays inobtaining

regulatory approval orpatent protection forourproduct candidates ;competition from other pharmaceutical orbiotechnology

companies ;expected timing ofclinical studies forthepotential Oravax Medical Inc.vaccine, itspotential advantages, safety and

efficacy and itspotential toprotect against COVID -19and variants thereof ;and ourability toobtain additional funding required

toconduct ourresearch, development and commercialization activities, and others, allofwhich could cause theactual results

orperformance ofOramed todiffer materially from those contemplated insuch forward -looking statements .Except as

otherwise required bylaw, Oramed undertakes noobligation topublicly release any revisions tothese forward -looking

statements toreflect events orcircumstances after thedate hereof ortoreflect theoccurrence ofunanticipated events .Fora

more detailed description ofthe risks and uncertainties affecting Oramed, reference ismade toOramed's reports filed from

time totime with theSecurities and Exchange Commission, which involve known and unknown risks, uncertainties and other

factors which may cause theactual results, performance orachievements ofthecompany, orindustry results, tobematerially

different from any future results, performance orachievements expressed orimplied bysuch forward -looking statements .

Please refer tothecompany's filings with theSecurities and Exchange Commission foracomprehensive listofrisk factors that

could cause actual results, performance orachievements ofthecompany todiffer materially from those expressed orimplied in

such forward -looking statements .Oramed undertakes noobligation toupdate orrevise anyforward -looking statements .3

Oramed © 2022Oramed Snapshot

Management Proprietary oral protein delivery platform

Diabetes first - initially targeting the lucrative insulin market

Robust pipeline leveraging IP portfolio for additional significant